

Antifungals as Novel Treatments for Melanoma?

Conclusion

In conclusion, we have identified TRPM2 as a target in the treatment of melanoma. Although TRPM2 has previously been identified as a target in several other cancers, the treatments of melanoma with antifungal agents that antagonize TRPM2 channels offer several advantages. Consequently, further studies involving the targeting of TRPM2 with imidazole antifungal agents represents promising research that may produce effective treatments for melanoma. These treatment options could emerge as alternatives to current regimens for melanoma patients. They could also serve as primary, first-line therapeutic agents for a defined subset of melanoma patients. And finally, antifungal agents could lead to effective preventative strategies so patients could avoid developing melanoma, the most aggressive type of skin cancer that arises in more and more patients each year.

References

1. Winder M, Viros A (2018) Mechanisms of drug resistance in melanoma. *Handb Exp Pharmacol* 249: 91-108.
2. Davis LE, Shalin SC, Tackett AJ (2019) Current state of melanoma diagnosis and treatment. *Cancer Biol Ther* 20: 1366-1379.
3. McKamey SG, Jira LR, Tweed CM, Blake SD Powell DP, et al. (2022) Antagonism of the transient receptor potential melastatin-2 channel leads to targeted antitumor effects in primary human malignant melanoma cells. *Inter J Oncol* 60: 43-55.
4. Sumoza-Toledo A, Penner R (2011) TRPM2: A Multifunctional ion channel for calcium signalling. *J Physiol* 589: 1515-1525.
5. Blake SD, Tweed CM, McKamey SG, Koh DW (2017) Transient Receptor Potential, Melastatin-2 (TRPM2) blockade: Perspectives on potential novel clinical utility in cancer. *Trans Cancer Res* 6: S342-S347.
6. Hill K, McNulty S, Randall AD (2004) Inhibition of TRPM2 channels by the antifungal agents clotrimazole and econazole. *Naunyn Schmiedebergs Arch Pharmacol* 37: 227-237.
7. Hara Y, Wakamori M, Ishii M, Maeno E, Nishida M, et al. (2002) LTRPC2 Ca²⁺-permeable channel activated by changes in redox status confers susceptibility to cell death. *Mol Cell* 9: 163-173.
8. Adinolfi B, Carpi S, Romanini A, Da Pozzo E, Castagna M, et al. (2015) Analysis of the antitumor activity of clotrimazole on A375 human melanoma cells. *Anticancer Res* 35: 3781-3786.
9. Zancan P, Rosas AO, Marcondes MC, Marinho-Carvalho MM, Sola-Penna M (2007) Clotrimazole inhibits and modulates heterologous association of the key glycolytic enzyme 6-phosphofructo-1-kinase. *Biochem Pharmacol* 73: 1520-1527.
10. Dong C., Yang R, Li H., Ke K, Luo C, et al. (2017) Econazole nitrate inhibits PI3K activity and promotes apoptosis in lung cancer cells. *Sci Reports* 7: 17987.
11. Davis EJ, Johnson DB, Sosman JA, Chandra S (2018) Melanoma: What do all the mutations mean? *Cancer* 124: 3490-3499.